• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

匹莫范色林治疗帕金森病精神病的作用机制：靶向5-羟色胺5HT2A和5HT2C受体

Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.

作者信息

Stahl Stephen M

出版信息

CNS Spectr. 2016 Aug;21(4):271-5. doi: 10.1017/S1092852916000407.

DOI:10.1017/S1092852916000407
PMID:27503570
Abstract

Pimavanserin, a novel agent approved for the treatment of Parkinson's disease psychosis, has potent actions as an antagonist/inverse agonist at serotonin 5HT2A receptors and less potent antagonist/inverse agonist actions at 5HT2C receptors.

摘要

匹莫范色林是一种被批准用于治疗帕金森病精神病的新型药物，它作为5-羟色胺5HT2A受体的拮抗剂/反向激动剂具有强效作用，而作为5HT2C受体的拮抗剂/反向激动剂作用则较弱。

相似文献

1
Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.匹莫范色林治疗帕金森病精神病的作用机制：靶向5-羟色胺5HT2A和5HT2C受体
CNS Spectr. 2016 Aug;21(4):271-5. doi: 10.1017/S1092852916000407.
2
Pimavanserin: An Inverse Agonist Antipsychotic Drug.匹莫范色林：一种反向激动剂抗精神病药物。
J Psychosoc Nurs Ment Health Serv. 2016 Jun 1;54(6):21-4. doi: 10.3928/02793695-20160523-01.
3
Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.帕金森病伴发精神病的治疗选择：重点介绍新批准药物——匹莫范色林。
CNS Neurol Disord Drug Targets. 2017;16(3):234-243. doi: 10.2174/1871527315666161006104347.
4
Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.匹莫范色林，一种用于治疗帕金森病精神病的新型抗精神病药物。
Expert Rev Clin Pharmacol. 2017 Nov;10(11):1161-1168. doi: 10.1080/17512433.2017.1369405. Epub 2017 Oct 17.
5
Pimavanserin as treatment for Parkinson's disease psychosis.匹莫范色林用于治疗帕金森病精神病。
Lancet. 2014 Feb 8;383(9916):494-6. doi: 10.1016/S0140-6736(13)62157-1. Epub 2013 Nov 1.
6
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.吡贝地尔治疗帕金森病精神病患者的随机、安慰剂对照 3 期试验。
Lancet. 2014 Feb 8;383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Epub 2013 Nov 1.
7
Pimavanserin.匹莫范色林
Drugs Today (Barc). 2015 Nov;51(11):645-52. doi: 10.1358/dot.2015.51.11.2404001.
8
Pimavanserin for the treatment of Parkinson's disease psychosis.吡贝地尔治疗帕金森病精神病。
Expert Opin Pharmacother. 2013 Oct;14(14):1969-75. doi: 10.1517/14656566.2013.819345.
9
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.匹莫范色林是一种5-羟色胺2A受体反向激动剂，可逆转帕金森病啮齿动物模型中的类精神病行为。
Behav Pharmacol. 2011 Oct;22(7):681-92. doi: 10.1097/FBP.0b013e32834aff98.
10
Pimavanserin for the treatment of Parkinson's disease psychosis.匹莫范色林用于治疗帕金森病精神病。
Expert Opin Pharmacother. 2016 Oct;17(15):2115-24. doi: 10.1080/14656566.2016.1234609. Epub 2016 Sep 15.

引用本文的文献

1
Role of the cholinergic system in the psychopathology and treatment of schizophrenia: a protocol for a scoping review.胆碱能系统在精神分裂症精神病理学及治疗中的作用：一项范围综述方案
Front Psychiatry. 2025 Jun 3;16:1593211. doi: 10.3389/fpsyt.2025.1593211. eCollection 2025.
2
The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature.非致幻性5-羟色胺2A受体（5-HT2A）药物在治疗物质使用障碍中的潜力：临床文献的叙述性综述
Expert Opin Pharmacother. 2025 Feb;26(2):133-146. doi: 10.1080/14656566.2024.2446623. Epub 2024 Dec 26.
3
ENHANCE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin for Schizophrenia in Patients With an Inadequate Response to Antipsychotic Treatment.
ENHANCE：一项针对抗精神病治疗反应不足的精神分裂症患者，使用匹莫范色林作为辅助治疗的3期随机双盲安慰剂对照研究。
Schizophr Bull Open. 2022 Jan 8;3(1):sgac006. doi: 10.1093/schizbullopen/sgac006. eCollection 2022 Jan.
4
The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson's disease psychosis: a 16-week, single-arm, open-label study.匹莫范色林治疗帕金森病精神病患者日常生活活动能力的效果：一项为期16周的单臂开放标签研究。
Ther Adv Neurol Disord. 2024 Mar 11;17:17562864241228350. doi: 10.1177/17562864241228350. eCollection 2024.
5
Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study.匹莫范色林治疗患有神经退行性疾病相关神经精神症状老年患者的安全性概况：一项3B期研究。
J Alzheimers Dis. 2024;98(1):265-274. doi: 10.3233/JAD-231167.
6
Novel Compounds in the Treatment of Schizophrenia-A Selective Review.精神分裂症治疗中的新型化合物——一项选择性综述
Brain Sci. 2023 Aug 11;13(8):1193. doi: 10.3390/brainsci13081193.
7
Pharmacophore modeling, molecular docking, and molecular dynamics studies to identify new 5-HTR antagonists with the potential for design of new atypical antipsychotics.基于药效团模型、分子对接和分子动力学研究，寻找新型 5-HT₅A 拮抗剂，为新型非典型抗精神病药物的设计提供潜在靶点。
Mol Divers. 2023 Oct;27(5):2217-2238. doi: 10.1007/s11030-022-10553-y. Epub 2022 Nov 21.
8
Pimavanserin and Parkinson's Disease Psychosis: A Narrative Review.匹莫范色林与帕金森病精神病：一项叙述性综述。
Brain Sci. 2022 Sep 23;12(10):1286. doi: 10.3390/brainsci12101286.
9
Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms.精神病在帕金森病中的新作用：从临床相关性到分子机制
World J Psychiatry. 2022 Sep 19;12(9):1127-1140. doi: 10.5498/wjp.v12.i9.1127.
10
Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma.药物再利用：一种开发胶质母细胞瘤有效治疗方法的快速通道策略
Cancers (Basel). 2022 Jul 29;14(15):3705. doi: 10.3390/cancers14153705.